Serge Saxonov - Aug 3, 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol
TXG
Transactions as of
Aug 3, 2021
Transactions value $
-$2,531,811
Form type
4
Date filed
8/4/2021, 04:48 PM
Previous filing
Jul 8, 2021
Next filing
Aug 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $26.2K +5.21K +0.58% $5.04* 909K Aug 3, 2021 Direct F1
transaction TXG Class A Common Stock Options Exercise $112K +9.79K +1.08% $11.48* 919K Aug 3, 2021 Direct F1
transaction TXG Class A Common Stock Sale -$300K -1.7K -0.18% $176.52 917K Aug 3, 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale -$790K -4.45K -0.49% $177.56 913K Aug 3, 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale -$1.42M -7.95K -0.87% $178.47 905K Aug 3, 2021 Direct F1, F4
transaction TXG Class A Common Stock Sale -$162K -904 -0.1% $179.35 904K Aug 3, 2021 Direct F1, F5
holding TXG Class A Common Stock 90K Aug 3, 2021 See Footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -5.21K -6.56% $0.00 74.2K Aug 3, 2021 Class A Common Stock 5.21K $5.04 Direct F1, F7
transaction TXG Stock Option (right to buy) Options Exercise $0 -9.79K -12.6% $0.00 67.9K Aug 3, 2021 Class A Common Stock 9.79K $11.48 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $175.995 to $176.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $177.00 to $177.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $178.00 to $178.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $179.03 to $179.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F7 This option, originally for 250,000 shares, of which 175,843 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F8 This option, originally for 145,786 shares, of which 77,865 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.